Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Multi-centre, Open-label, Phase 1a/b Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety, Tolerability, and Antitumour Activity in Patients With Advanced Liver Cancer

NCT02716012 is registered in ClinicalTrials.gov with Mina Alpha Limited as lead sponsor.

NCT NCT02716012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02716012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Multi-centre, Open-label, Phase 1a/b Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety, Tolerability, and Antitumour Activity in Patients With Advanced Liver Cancer
Lead sponsor
Mina Alpha Limited
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2016
Completion date
July 31, 2025
Enrollment
75 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver cancer